The future of drug discovery and development: Shifting emphasis towards personalized medicine

DOI: 10.1016/j.techfore.2009.09.005
Technological Forecasting and Social Change, 2010, 77, 203-21

#	Paper	IF	Citations
60	Bipodal PEGylated alkanethiol for the enhanced electrochemical detection of genetic markers involved in breast cancer. *Biosensors and Bioelectronics*, **2010**, 26, 1500-6	11.8	24
59	Electrochemical genosensor based on three-dimensional DNA polymer brushes monolayers. *Electrochemistry Communications*, **2011**, 13, 1155-1158	5.1	9
58	Linking molecular biomarkers with higher level condition indicators to identify effects of copper exposures on the endangered delta smelt (Hypomesus transpacificus). *Environmental Toxicology and Chemistry*, **2011**, 30, 290-300	3.8	24
57	Improving oncology outcomes through targeted therapeutics will require electronic delivery systems. *Future Oncology*, **2011**, 7, 649-56	3.6	4
56	In silico screening of indinavir-based compounds targeting proteolytic activity in HIV PR: binding pocket fit approach. *Medicinal Chemistry Research*, **2012**, 21, 4060-4068	2.2	27
55	An empirical study of commercialization performance on nanoproducts. *Technovation*, **2012**, 32, 168-178	7.9	28
54	Market challenges facing academic research in commercializing nano-enabled implantable devices for in-vivo biomedical analysis. *Technovation*, **2012**, 32, 193-204	7.9	40
53	Exploration and exploitation within and across intra-organisational domains and their reactions to firm-level failure. *Technology Analysis and Strategic Management*, **2012**, 24, 129-149	3.2	12
52	Big Pharma, Little Science? A Bibliometric Perspective on Big Pharma R&D Decline. *SSRN Electronic Journal*, **2012**,	1	4
51	The herbivore prescription. 78-100		6
50	Rapid DNA hybridization in microfluidics. *TrAC - Trends in Analytical Chemistry*, **2012**, 33, 9-22	14.6	18
49	A prospective overview of the essential requirements in molecular modeling for nanomedicine design. *Future Medicinal Chemistry*, **2013**, 5, 929-46	4.1	8
48	The pharmaceutical technology landscape: A new form of technology roadmapping. *Technological Forecasting and Social Change*, **2013**, 80, 194-211	9.5	64
47	The Anticipation of Converging Industries. **2013**,		26
46	Mesoporous gadolino-aluminosilicate nanoparticles as magnetic resonance imaging contrast agents. *Journal of Materials Chemistry B*, **2013**, 1, 1219-1222	7.3	6
45	Conceptual Framework and Research Design. **2013**, 127-171		0
44	Use of optical imaging to progress novel therapeutics to the clinic. *Journal of Controlled Release*, **2013**, 172, 523-34	11.7	25

43	Design of an implantable nano-enabled biomedical device for in-vivo glucose monitoring. **2014**,		
42	Modeling Drug Delivery in Gravity-Driven Microfluidic System. **2014**,		1
41	A consumer adoption model for personalized medicine: an exploratory study. *International Journal of Pharmaceutical and Healthcare Marketing*, **2014**, 8, 371-391	1.3	2
40	Clinical Translation and Regulations of Theranostics. **2014**, 439-456		3
39	Big Pharma, little science?. *Technological Forecasting and Social Change*, **2014**, 81, 22-38	9.5	77
38	Path-breaking target therapies for lung cancer and a far-sighted health policy to support clinical and cost effectiveness. *Health Policy and Technology*, **2014**, 3, 74-82	4.8	43
37	Personal Wellness: Complex and Elusive Product and Distributed Self-services. *Procedia CIRP*, **2014**, 16, 283-288	1.8	9
36	Converging scientific fields and new technological paradigms as main drivers of the division of scientific labour in drug discovery process: the effects on strategic management of the R&D corporate change. *Technology Analysis and Strategic Management*, **2014**, 26, 733-749	3.2	59
35	A new look at the corporate capability of personalized medicine development in the pharmaceutical industry. *R and D Management*, **2015**, 45, 94-103	4.1	3
34	Automated tumor analysis for molecular profiling in lung cancer. *Oncotarget*, **2015**, 6, 27938-52	3.3	30
33	How stakeholder shape innovation in controversial industries: the biotechnology industry in Germany. *Uwf UmweltWirtschaftsForum*, **2015**, 23, 77-86		3
32	Combining the scenario technique with bibliometrics for technology foresight: The case of personalized medicine. *Technological Forecasting and Social Change*, **2015**, 98, 137-156	9.5	28
31	External environment, the innovating organization, and its individuals: A multilevel model for identifying innovation barriers accounting for social uncertainties. *Journal of Engineering and Technology Management - JET-M*, **2015**, 35, 45-70	3.7	41
30	A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics. *Frontiers in Genetics*, **2015**, 6, 357	4.5	9
29	Innovation through M&A in the biopharmaceutical sector. *Strategic Direction*, **2016**, 32, 27-29	0.6	1
28	The knowledge production model of the New Sciences: The case of Translational Medicine. *Technological Forecasting and Social Change*, **2016**, 111, 12-21	9.5	4
27	Problem-driven innovations in drug discovery: Co-evolution of the patterns of radical innovation with the evolution of problems. *Health Policy and Technology*, **2016**, 5, 143-155	4.8	45
26	3D bioprinting for drug discovery and development in pharmaceutics. *Acta Biomaterialia*, **2017**, 57, 26-46	10.8	162

25	Sources of technological innovation: Radical and incremental innovation problem-driven to support competitive advantage of firms. *Technology Analysis and Strategic Management*, **2017**, 29, 1048-1061	3.2	138
24	Designer bacteria as intratumoural enzyme biofactories. *Advanced Drug Delivery Reviews*, **2017**, 118, 8-23	18.5	15
23	Bioinformatics for Diseases Management: A Personalized Therapeutics Prospective. **2017**, 187-199		
22	Santé digitale´: promesses, défis et craintes. Une revue de la littérature. *Pratiques Psychologiques*, **2017**, 23, 61-77	0.3	8
21	Radical and Incremental Innovation Problem-Driven to Support Competitive Advantage of Firms. *SSRN Electronic Journal*, **2017**,	1	1
20	Emerging Technology in Cartilage Repair: Analysis with a Substitution Model of Technological Change. *SSRN Electronic Journal*, **2017**,	1	1
19	Balancing comprehensiveness and parsimony: Towards a context-specific barrier identification across multiple levels combined with complexity reduction through barrier groups. *Journal of Engineering and Technology Management - JET-M*, **2018**, 49, 46-59	3.7	1
18	3D bioprinting of tissues and organs for regenerative medicine. *Advanced Drug Delivery Reviews*, **2018**, 132, 296-332	18.5	232
17	Understanding and utilizing the biomolecule/nanosystems interface. **2018**, 207-297		10
16	Uncovering the dynamics of market convergence through M&A. *Technological Forecasting and Social Change*, **2019**, 138, 95-114	9.5	16
15	What to expect from assisted reproductive technologies? Experts' forecasts for the next two decades. *Technological Forecasting and Social Change*, **2019**, 148, 119722	9.5	6
14	Scaffold-free bioprinted osteogenic and chondrogenic systems to model osteochondral physiology. *Biomedical Materials (Bristol)*, **2019**, 14, 065010	3.5	7
13	Co-evolutionary and systemic study on the evolution of emerging stem cell-based therapies. *Technological Forecasting and Social Change*, **2019**, 138, 324-339	9.5	3
12	Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak. *Viruses*, **2020**, 12,	6.2	28
11	Are bibliometric measures consistent with scientists' perceptions? The case of interdisciplinarity in research. *Scientometrics*, **2021**, 126, 7477-7502	3	1
10	Artificial Intelligence in 3D Printing: A Revolution in Health Care. *Lecture Notes in Bioengineering*, **2022**, 57-79	0.8	2
9	Path-Breaking Innovations for Lung Cancer: A Revolution in Clinical Practice. *SSRN Electronic Journal*,	1	17
8	The Biological Significance of Nano-Interactions. *Springer Series in Biophysics*, **2013**, 1-20		

7	Geschäftsmodelle in der Personalisierten Medizin – Konzeptioneller Rahmen zum Status Quo und Perspektiven. **2015**, 1-37		1
6	Der Wandel dominanter Geschäftslogiken durch die Personalisierte Medizin. **2015**, 39-66		
5	Quo vadis artificial intelligence and personalized medicine?. *Future Drug Discovery*,	2	
4	Advances in microfluidic 3D cell culture for preclinical drug development.. *Progress in Molecular Biology and Translational Science*, **2022**, 187, 163-204	4	2
3	System and network biology-based computational approaches for drug repositioning. **2022**, 267-290		2
2	Application of Calcium Alginate Hydrogels in Semi-solid Extrusion 3D Printing for the Production of Easy-to-Swallow Tablets.		0
1	Concluding Thoughts. **2023**, 215-226		0